[Form 4] Amgen Inc Insider Trading Activity

Rhea-AI Filing Summary

Amgen director S. Omar Ishrak reported the acquisition of 121.4308 shares of Amgen common stock on 08/08/2025 via vested restricted stock units under the Amgen Inc. 2009 Director Incentive Program. The transaction is shown at a $0 price, reflecting issuance of shares upon vesting, and the Form 4 was signed on 08/09/2025.

The filing reports 6,241.9302 shares beneficially owned following the transaction, held directly. The reported shares include 291 Dividend Equivalents credited to vested but deferred RSUs and payable in shares under a dividend reinvestment arrangement. The document identifies the reporting person as a director of Amgen (AMGN).

Insights

Corporate Governance Expert

Routine director equity vesting increases direct holdings by 121.4308 shares; filing is standard disclosure.

The Form 4 discloses a vesting of Restricted Stock Units under the company's Director Incentive Program resulting in the issuance of 121.4308 shares at a reported price of $0, and a post-transaction direct beneficial ownership of 6,241.9302 shares. The filing also notes 291 Dividend Equivalents credited on vested but deferred RSUs. From a governance perspective, this is a routine compensation event and provides transparent reporting of a director's equity stake without indications of unusual timing or terms in the document itself.

Securities Analyst

Insider received vested RSUs converted to 121.4308 shares; disclosure is informational and not materially market-moving.

The reporting shows the derivative award (RSUs) vested and were settled in common stock on 08/08/2025, with the Form signed 08/09/2025. The transaction price is recorded as $0, consistent with vesting settlement rather than an open-market purchase. Total direct beneficial ownership is reported as 6,241.9302 shares. The filing contains no indication of derivative exercises, sales, or purchases beyond the vested RSU settlement disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ISHRAK OMAR

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		A		121.4308	A	$0	6,241.9302(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

2. These shares include 291 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

	/s/ S. Omar Ishrak	08/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for AMGN?

The Form 4 was filed by S. Omar Ishrak, identified as a director of Amgen Inc.

What transaction is reported on the AMGN Form 4?

The filing reports the acquisition of 121.4308 shares via vested Restricted Stock Units on 08/08/2025.

What was the reported price for the shares on the Form 4?

The transaction is reported at a price of $0, reflecting shares issued upon vesting of RSUs.

How many shares does the reporting person beneficially own after the transaction?

The Form reports 6,241.9302 shares beneficially owned following the reported transaction.

Does the filing mention Dividend Equivalents (DEs)?

Yes. The filing states the reported shares include 291 Dividend Equivalents credited on vested but deferred RSUs and payable in shares.

When was the Form 4 signed?

The signature on the Form is dated 08/09/2025.